SCHEMBL23519683

SCHEMBL23519683

C=Cc1cc2ncn(C)c2c(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.36
DPP8 Q6V1X1 3/20 0.31
ADORA2B P29275 1/20 0.31
IP6K1 Q92551 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17563255 0.75 DPP4 (0.36) DPP4DPP8ADORA2B
SCHEMBL29669299 0.74 DPP4 (0.35) DPP4DPP8ADORA2B
SCHEMBL20512424 0.74 DPP4 (0.42) DPP4DPP8ADORA2B
SCHEMBL24463371 0.74 DPP4 (0.35) DPP4DPP8ADORA2B
SCHEMBL18911879 0.73 TDO2 (0.31)
SCHEMBL18912157 0.73 DYRK1A (0.39) DPP4
SCHEMBL17694882 0.71 DPP4 (0.34) DPP4
SCHEMBL13676391 0.70 DPP4 (0.38) DPP4DPP8ADORA2B
SCHEMBL24463141 0.69 DPP4 (0.38) DPP4DPP8
SCHEMBL30430122 0.69 DPP4 (0.35) DPP4DPP8ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND KDM1B, KDM1A, DOT1L DPP4 3255/4885DPP8 3473/4885ADORA2B 2246/4885
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF KDM1B, KDM1A, HDAC1 DPP4 1929/4885DPP8 2160/4885ADORA2B 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.